ChiCTR2100053322 版本V1.4 版本创建时间2022/04/01 10:42:39 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100053322 

最近更新日期:

Date of Last Refreshed on:

2022-04-01 10:39:55 

注册时间:

Date of Registration:

2021-11-18 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

芳香疗法在造血干细胞移植患者隔离期症状管理效果研究

Public title:

the effect of aromatherapy in symptom management of patients with hematopoietic stem cell transplantation during isolation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

芳香疗法在造血干细胞移植患者隔离期症状管理效果研究

Scientific title:

the effect of aromatherapy in symptom management of patients with hematopoietic stem cell transplantation during isolation

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘娟娟 

研究负责人:

刘娟娟 

Applicant:

Liujuanjuan 

Study leader:

Liujuanjuan 

申请注册联系人电话:

Applicant telephone:

13732254945

研究负责人电话:

Study leader's telephone:

13732254945

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

hjy815@yeah.net

研究负责人电子邮件:

Study leader's E-mail:

hjy815@yeah.net

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市余杭区新明半岛雨径轩

研究负责人通讯地址:

浙江省杭州市余杭区新明半岛雨径轩

Applicant address:

Yujingxuan, Xinming Peninsula, Yuhang District, Hangzhou City, Zhejiang Province

Study leader's address:

Yujingxuan, Xinming Peninsula, Yuhang District, Hangzhou City, Zhejiang Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

浙江大学医学院附属第一医院

Applicant's institution:

First Affiliated Hospital of Zhejiang University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

浙大一院伦审2022研第020号-会

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

浙江大学医学院附属第一医院临床研究伦理委员会

Name of the ethic committee:

Clinical Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022-03-17 00:00:00

伦理委员会联系人:

焦杨文

Contact Name of the ethic committee:

Jiao Yangwen

伦理委员会联系地址:

浙江省杭州市上城区庆春路79号

Contact Address of the ethic committee:

79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

浙江大学医学院附属第一医院

Primary sponsor:

First Affiliated Hospital of Zhejiang University

研究实施负责(组长)单位地址:

浙江省杭州市余杭区文一西路1367号

Primary sponsor's address:

1367 Wenyi West Road, Yuhang District, Hangzhou City, Zhejiang Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江大学医学院附属第一医院

具体地址:

余杭区文一西路1367号

Institution
hospital:

The First Affiliated Hospital of Zhejiang University

Address:

1367 Wenyi Road West, Yuhang District

经费或物资来源:

浙江大学医学院附属第一医院

Source(s) of funding:

First Affiliated Hospital of Zhejiang University

Target disease:

Hematopoietic stem cell transplantation

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

(1)采用随机对照研究方法,评价芳香疗法对改善造血干细胞移植患者隔离期间症状管理有效性及可行性。 (2)发挥芳香疗法的作用,为管理造血干细胞隔离期间症状管理提供新思路,将研究结果应用于临床并进行推广。  

Objectives of Study:

(1)A randomized controlled study method was used to evaluate the effectiveness and feasibility of aromatherapy in improving the symptom management of patients with hematopoietic stem cell transplantation during isolation. (2)Give full play to the role of aromatherapy, provide new ideas for the management of symptoms during hematopoietic stem cell isolation, apply the research results to the clinic and promote them.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①行异基因造血干细胞移植的恶性血液病患者
②年龄大于18岁,性别不限
③会填写问卷调查
④自愿参加本实验

Inclusion criteria

①Patients with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation
②Patients who are older than 18 years old and have no gender limitation
③Patients who will fill out the questionnaire
④Patients who volunteered to participate in this experiment

排除标准:

①对薰衣草精油过敏者
②预计生存时间小于一个月
③预处理前有焦虑史、抑郁史
④有其他雌激素依赖性肿瘤患者

Exclusion criteria:

①Patients who are allergic to lavender essential oil
②Patients whose estimated survival time is less than one month
③Patients with a history of anxiety or depression before pretreatment
④Patients with other estrogen-dependent tumors

研究实施时间:

Study execute time:

From 2022-01-01 00:00:00 To 2023-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-01-01 00:00:00 To 2023-12-31 00:00:00  

干预措施:

Interventions:

组别:

试验组

样本量:

50

Group:

Experimental group

Sample size:

干预措施:

薰衣草吸入

干预措施代码:

Intervention:

Lavender inhalation

Intervention code:

组别:

对照组

样本量:

50

Group:

Control group

Sample size:

干预措施:

常规护理

干预措施代码:

Intervention:

Routine care

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

杭州 

Country:

China 

Province:

Zhejiang 

City:

Hangzhou 

单位(医院):

浙江大学医学院附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Zhejiang University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

睡眠

指标类型:

主要指标

Outcome:

Sleep

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛

指标类型:

次要指标

Outcome:

pain

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

焦虑抑郁

指标类型:

主要指标

Outcome:

Anxiety and depression

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

恶心呕吐

指标类型:

次要指标

Outcome:

Nausea and vomiting

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

造血干细胞植入

指标类型:

次要指标

Outcome:

Hematopoietic stem cell implantation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

由研究人员使用SPSS软件进行随机分为实验组和对照组

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomly divided into experimental group and control group by researchers using SPSS software

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2024-03-01,采用网络平台,ResMan (www.medresman.org)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2024-03-01,ResMan (www.medresman.org)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

纸质的病例记录表、电子数据采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form,Electronic Data Capture, EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-11-18 23:16:49